Oxidative stress has been strongly implicated in both the inflammatory and neurodegenerative pathological mechanisms in multiple sclerosis (MS). In response to oxidative stress, cells increase and activate their cellular antioxidant mechanisms. Glutathione (GSH) is the major antioxidant in the brain, and as such plays a pivotal role in the detoxification of reactive oxidants. Previous research has shown that GSH homeostasis is altered in MS. In this review, we provide a comprehensive overview on GSH metabolism in brain cells, with a focus on its involvement in MS. The potential of GSH as an in vivo biomarker in MS is discussed, along with a short overview of improvements in imaging methods that allow non-invasive quantification of GSH in the brain. These methods might be instrumental in providing real-time measures of GSH, allowing the assessment of the oxidative state in MS patients and the monitoring of disease progression. Finally, the therapeutic potential of GSH in MS is discussed.
Van HorssenJWitteMESchreibeltG. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta2011; 1812: 141–150.
3.
JohnsonWMWilson-DelfosseALMieyalJJ. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients2012; 4: 1399–1440.
4.
DringenRHirrlingerJ. Glutathione pathways in the brain. Biologic Chem2003; 384: 505–516.
5.
FischerMTSharmaRLimJL. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain2012; 135: 886–899.
6.
HaiderLFischerMTFrischerJM. Oxidative damage in multiple sclerosis lesions. Brain2011; 134: 1914–1924.
7.
Van HorssenJSchreibeltGDrexhageJ. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biol Med2008; 45: 1729–1737.
8.
GrayEThomasTLBetmouniS. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci Lett2008; 444: 195–198.
9.
BoLDawsonTMWesselinghS. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol1994; 36: 778–786.
10.
WitteMEGeurtsJJDe VriesHE. Mitochondrial dysfunction: A potential link between neuroinflammation and neurodegeneration?Mitochondrion2010; 10: 411–418.
11.
DuttaRMcDonoughJYinX. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol2006; 59: 478–489.
12.
MahadDJZiabrevaICampbellG. Mitochondrial changes within axons in multiple sclerosis. Brain2009; 132: 1161–1174.
13.
WitteMEMahadDJLassmannH. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Molec Med2014; 20: 179–187.
14.
SchreibeltGMustersRJReijerkerkA. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J Immunol2006; 177: 2630–2637.
15.
Van der GoesAWoutersDVan der PolSM. Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro. Faseb J2001; 15: 1852–1854.
16.
Van der GoesABrouwerJHoekstraK. Reactive oxygen species are required for the phagocytosis of myelin by macrophages.J Neuroimmunol1998; 92: 67–75.
DringenR. Metabolism and functions of glutathione in brain. Prog Neurobiol2000; 62: 649–671.
19.
De VriesHEWitteMHondiusD. Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease?Free Radical Biol Med2008; 45: 1375–1383.
20.
Fernandez-FernandezSAlmeidaABolanosJP. Antioxidant and bioenergetic coupling between neurons and astrocytes. The Biochem J2012; 443: 3–11.
21.
DringenRGuttererJMHirrlingerJ. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem2000; 267: 4912–4916.
22.
AoyamaKSuhSWHambyAM. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nature Neurosci2006; 9: 119–126.
23.
CalabreseVScapagniniGRavagnaA. Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res2002; 70: 580–587.
24.
WernerPPittDRaineCS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol2001; 50: 169–180.
25.
GrasGSamahBHubertA. EAAT expression by macrophages and microglia: Still more questions than answers. Amino Acids2012; 42: 221–229.
26.
MannCLDaviesMBBoggildMD. Glutathione S-transferase polymorphisms in MS: Their relationship to disability. Neurology2000; 54: 552–557.
27.
TajouriLMellickASAshtonKJ. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res2003; 119: 170–183.
28.
JensenGEGissel-NielsenGClausenJ. Leucocyte glutathione peroxidase activity and selenium level in multiple sclerosis. J Neurolog Sci1980; 48: 61–67.
29.
CalabreseVRaffaeleRCosentinoE. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res1994; 14: 119–123.
30.
SorensenPSHansenJCMaiJ. Lymphocyte glutathione peroxidase activity during exacerbations in multiple sclerosis. Biolog Trace Element Res1992; 33: 145–150.
31.
SzeinbergAGolanRBen-EzzerJ. Glutathione peroxidase activity in various types of blood cells in multiple sclerosis. Acta Neurol Scand1981; 63: 67–75.
32.
GuyJEllisEAHopeGM. Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental optic neuritis. Arch Ophthalmol1989; 107: 1359–1363.
33.
LjubisavljevicSStojanovicICvetkovicT. Glutathione homeostasis disruption of erythrocytes, but not glutathione peroxidase activity change, is closely accompanied with neurological and radiological scoring of acute CNS inflammation. Neuroimmunomodulation2014; 21: 13–20.
34.
ChoiIYLeeSPDenneyDR. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler2011; 17: 289–296.
35.
SrinivasanRRatineyHHammond-RosenbluthKE. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magnet Res Imag2010; 28: 163–170.
36.
CacciatoreIBaldassarreLFornasariE. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxidat Med Cell Longev2012; 2012: 240146.
LjubisavljevicSStojanovicIPavlovicD. Aminoguanidine and N-acetyl-cysteine supress oxidative and nitrosative stress in EAE rat brains. Redox Rep2011; 16: 166–172.
39.
StanislausRGilgAGSinghAK. N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmune Dis2005; 2: 4.
40.
LinSXLisiLDello RussoC. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro2011; 3.
41.
LinkerRALeeDHRyanS. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011; 134: 678–692.
42.
ScannevinRHChollateSJungMY. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther2012; 341: 274–284.
43.
FoxRJKitaMCohanSL. BG-12 (dimethyl fumarate): A review of mechanism of action, efficacy and safety. Curr Med Res Opin2014; 30: 251–262.
